<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Busse, Gregory</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Thase, Michael E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Late Breaking Clinical Trials: Quetiapine as Potential First-Line Treatment in Acute Bipolar II Depression</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with bipolar II disorder can be particularly difficult to treat, as they are sensitive to the side effects of treatment and more susceptible to treatment-emergent rapid cycling and shifts in affect. Currently there is not enough evidence to select one agent over another in terms of first-line therapy. This article presents results of quetiapine monotherapy in the treatment of acute depression in patients with bipolar II disorder.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>